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 24 
ABSTRACT 25 
Purpose: Clostridium difficile, methicillin resistant Staphylococcus aureus (MRSA) and 26 
vancomycin resistant enterococci (VRE) are worldwide prevalent healthcare associated 27 
pathogens. We have evaluated three Qiagen artus QS-RGQ assays for the detection of 28 
these pathogens. 29 
 30 
0HWKRGV:HH[DPLQHG stool samples previously tested for C. difficile infection, 94 31 
rectal swabs previously screened for VRE, and 200 MRSA screening nasal swabs.  32 
 33 
Results: With the routine diagnostic laboratory results being adopted as the gold 34 
standard, the sensitivity, specificity, PPVs and NPVs of the artus C. difficile assay were 35 
100%, for the artus VanR QS-RGQ assay, 95%, 68%, 44% and 98%, and for the 36 
MRSA/SA artus assay, 80%, 94%, 93% and 83%, respectively. The artus VanR assay 37 
detected the vanA and/or vanB gene in 32% of culture-negative VRE screens, in 71% of 38 
these cases only vanB was detected. An over-estimation of the rate of faecal VRE 39 
colonisation could be due to a patient population with high rates of faecal carriage of 40 
non-enterococcal species carrying vanB.  41 
 42 
Conclusions: Based on our findings we conclude that all three artus QS-RGQ assays 43 
could be a useful addition to a diagnostic laboratory, and that optimal choice of assay 44 
should be determined according to user needs.  45 
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INTRODUCTION:  48 
Healthcare-associated infections (HCAIs) are a major cause of morbidity and mortality. 49 
[1-3] HCAIs can affect patients in any type of setting where they receive care and 50 
represent the most frequent adverse event in health care delivery worldwide. [4] Recent 51 
systematic reviews have estimated hospital-wide prevalence of HCAIs in high-income 52 
countries at 7.6% and in low and middle-income countries at 10.1%. [4] Clostridium 53 
difficile, methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant 54 
enterococci (VRE) are three HCAI pathogens that are particularly prevalent worldwide.  55 
 56 
&ORVWULGLXPGLIILFLOHLQIHFWLRQ&',LVFRQVLGHUHGWKHPRVWFRPPRQFDXVHRIQRVRFRPLDO57 
LQIHFWLRXVGLDUUKRHDamong adults in the developed world. [5]7KHLQIHFWLRQLVUHODWHGWR58 
DQWLELRWLFXVHDQGLVDVVRFLDWHGZLWKWKHRYHUJURZWKRI&GLIILFLOHDQGWKHSURGXFWLRQRI59 
WR[LQV$DQGRU%7KHVHWR[LQVFDXVHDUDQJHRIHIIHFWVLQFOXGLQJPLOGWRVHYHUH60 
GLDUUKRHDJXWPXFRVDOGDPDJHFROLWLVDQGSVHXGRPHPEUDQRXVFROLWLV5HFHQWILJXUHV61 
UHSRUW&',DVDQQXDOO\FDXVLQJ1600 deaths in England and Wales, and 29000 deaths 62 
in the USA. [6,7] Since the clinical features of health care-associated diarrhea cannot 63 
reliably distinguish C. difficile from other causes, laboratory confirmation is essential. 8.64 
	(XURSHDQJXLGHOLQHVRQWKHGLDJQRVLVRI&',UHFRPPHQGJOXWDPDWHGHK\GURJHQDVH65 
*'+(,$RUQXFOHLFDFLGDPSOLILFDWLRQWHVWLQJ1$$7WRVFUHHQVDPSOHVIROORZHGE\D66 
VHQVLWLYHWR[LQGHWHFWLRQPHWKRG>@ 67 
 68 
4 
 
Vancomycin-resistant enterococci (VRE) are now amongst the most common HCAI 69 
multidrug-resistant organisms. [9,10] 5LVNIDFWRUVIRUQRVRFRPLDOWUDQVPLVVLRQRI95(70 
LQFOXGHSURORQJHGKRVSLWDOL]DWLRQXVHRIEURDGVSHFWUXPDQWLPLFURELDOVDQGSULRU71 
VXUJHU\95(FDXVHDUDQJHRILQIHFWLRQVLQFOXGLQJEORRGVWUHDPLQWUD-DEGRPLQDO72 
VXUJLFDO-VLWHDQGXULQDU\WUDFWLQIHFWLRQV>@Altogether, eight types of acquired 73 
vancomycin resistance genotypes are known in enterococci with vanA being the most 74 
prevalent genotype worldwide followed by vanB. [12, 13] Phenotypically the vanA gene 75 
mediates a high-level of resistance to vancomycin and teicoplanin whereas the vanB 76 
gene confers low- to moderate-level resistance to vancomycin only. Low level 77 
vancomycin resistance expression, especially in vanB strains, may complicate 78 
performance of diagnostic assays assessing the resistance phenotype and predicting 79 
the corresponding genotype. During recent years, clusters of infections and 80 
colonisations with vanB genotype E. faecium increased in a number of European 81 
countries. [12] 82 
 83 
MRSA is an important cause of HCAIs and community-acquired infections. [14, 15] 84 
Patients colonized with MRSA serve as reservoirs for auto-infection and/or 85 
dissemination to other patients  and healthcare workers. [16, 17] Conventional 86 
screening of MRSA is performed using selective and differential agar media, but the 87 
results are not available before 18-48 hrs and interpretation can be subjective. Faster 88 
detection can be achieved by using PCR-based assays. There is ongoing debate 89 
regarding which tests are more appropriate for screening programmes. The increased 90 
5 
 
cost of rapid tests may be offset by savings as a result of reduced cross infection, fewer 91 
complications, and better utilization of beds. [18, 19]  92 
Rapid and accurate detection of CDI, MRSA and VRE is required WRHQVXUHSDWLHQWV93 
UHFHLYHDSSURSULDWHantimicrobial treatment and optimised infection prevention 94 
interventions. 4,$*(1KDVGHYHORSHGUHDO-WLPHPXOWLSOH[3&5DVVD\VIRUGHWHFWLRQRI95 
WKHVHWKUHH+&$,SDWKRJHQV7KHDUWXV&GLIILFLOH46-5*4DVVD\&(PDUNHGDQG)'$96 
FOHDUHGGHWHFWVWKHWFG$DQGWFG%JHQHVWKDWHQFRGHIRU&GLIILFLOHWR[LQ$DQGWR[LQ%97 
UHVSHFWLYHO\WKHDUWXV9DQ546-5*4&(PDUNHGDVVD\GHWHFWVWKHYDQ$DQGYDQ%98 
JHQHVRIHQWHURFRFFLthe artus MRSA/SA QS-RGQ assay (CE marked) detects the 99 
lhd1, mecA and mecC genes of MRSA. :HKDYHHYDOXDWHGWKHSHUIRUPDQFHRIWKHVH100 
WKUHHPROHFXODUDVVD\VLQFRPSDULVRQZLWKFRQYHQWLRQDOWHVWLQJPHWKRGV. 101 
 102 
MATERIALS AND METHODS: 103 
:HFRPSDUHGWKHSHUIRUPDQFHRIWKH4,$*(1DUWXVDVVD\VQIAGEN, GmbH, Hilden, 104 
Germany) ZLWKWKHURXWLQHLGHQWLILFDWLRQPHWKRGVDWWKH/HHGV7HDFKLQJ+RVSLWDOV1+6105 
7UXVW/7+70LFURELRORJ\'HSW7KHDUWXVDVVD\VZHUHSHUIRUPHGRQWKHDXWRPDWHG106 
4,$V\PSKRQ\5*4V\VWHP4,$*(1All samples tested were selected from those 107 
submitted to the routine laboratories. 108 
 109 
Qiagen artus C. difficile assay 110 
$WRWDORIstool samples received by the routine enteric laboratory between 111 
December 2013 and May 2014 IURPSDWLHQWVDJHG 2 years was selected for inclusion 112 
in the study. All samples were diarrheal (adopting the shape of the container), had been 113 
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submitted for glutamate dehydrogenase (GDH) detection and cytotoxin testing (CTT), 114 
and had sufficient material to allow for all testing required. 7KHVWXG\VHWFRPSULVHG115 
VSHFLPHQVSUHYLRXVO\IRXQGWREHSRVLWLYHIRUERWK*'+DQWLJHQDQGF\WRWR[LQ116 
SURGXFWLRQDQG*'+-QHJDWLYHVSHFLPHQV6DPSOHVSUHYLRXVO\*'+DQGF\WRWR[LQ117 
positive were between one day and four months old at the time of testing, negative 118 
samples were processed within one week of collection. All samples were stored at 2-119 
5°C prior to testing. S DPSOHVZHUHSURFHVVHGZLWKWKHDUWXV&GLIILFLOH46-5*4DVVD\120 
DFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQV3UHYLRXVO\*'+&77-SRVLWLYHVWRROVDPSOHV121 
ZHUHUH-DQDO\]HGIRUWKHGDH DQWLJHQXVLQJWhe C diff Chek-60 glutamate GDH assay 122 
7HFKODE%ODFNVEXUJ9$86$DFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQVand also for 123 
the presence of cytotoxin. In brief, stool samples were first diluted 1:5 in phosphate-124 
buffered saline before being centrifuged, 20 µl of supernatant were then added to 125 
duplicate Vero cell monolayers. One these had been protected by the addition of 20 µl 126 
Clostridium sordelli antitoxin (Prolab Diagnostics, UK). Vero cells were grown in 96-well 127 
flat-bottomed microtitre trays in 160 µl of Dulbecco medium. A positive result was 128 
recorded if cell rounding was observed in the unprotected cells only, after 24 or 48 129 
hours of incubation at 37°C in the presence of CO2. 130 
 131 
4LDJHQDUWXV9DQ546-5*4DVVD\ 132 
Twenty rectal swabs positive for VRE, DVGHWHUPLQHGE\FXOWXUHRQKanamycin Aesculin 133 
Azide (.$$DJDUSOXVYDQFRP\FLQ(	2/DERUDWRULHVBonnybridge, ScotlandDQG134 
VXEVHTXHQW0$/',-72)DQDO\VLVZHUHFROOHFWHGIURPLQSDWLHQWVGXULQJ$SULODQG0D\135 
$IXUWKHUVRE culture-negative rectal swabs collected during this period were 136 
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also examined.Transport swabs containing Aimes Medium with charcoal were used 137 
(Thermo Fisher Scientific, Loughborough, UK). $OOVDPSOHVZHUHVWRUHGDW-&SULRUWR138 
DQDO\VLVDQGZHUHSURFHVVHGXVLQJWKHDUWXV9DQ546-5*4DVVD\DVSHU139 
PDQXIDFWXUHU¶VLQVWUXFWLRQV 140 
 141 
4LDJHQDUWXV056$46-5*4DVVD\ 142 
In total, 200 nasal swabs processed by the MRSA screening laboratory between 143 
January and June 2014 were retrospectively selected for inclusion in the study. 144 
Transport swabs containing Aimes Medium with charcoal were used (Thermo Fisher 145 
Scientific, Loughborough, UK). One hundred of these samples had previously been 146 
determined MRSA positive and 100 MRSA negative, by culture on Brilliance MRSA 2 147 
Agar (Oxoid, Basingstoke, UK). $OOVDPSOHVZHUHVWRUHGDW-&SULRUWRDQDO\VLV7KH148 
056$-SRVLWLYHVDPSOHVZHUHEHWZHHQWKUHHZHHNVDQGILYHPRQWKVROGDWWKHWLPHRI149 
WHVWLQJDOOQHJDWLYHVDPSOHVZHUHSURFHVVHGZLWKLQRQHZHHN3UHYLRXVO\056$-150 
SRVLWLYHVDPSOHVZHUHILUVWLQRFXODWHGRQWR%ULOOLDQFH056$FXOWXUHPHGLXPDQG151 
VXEVHTXHQWO\SURFHVVHGXVLQJWKHDUWXV056$46-5*4DVVD\. Previously MRSA-152 
negative swabs were processed with the artus assay but were not inoculated onto the 153 
culture medium. Sample preparation for the artus assay involved placing the swabs into 154 
tubes containing 2.5 ml eNat medium (Copan, Brescia, Italy) followed by vigorous 155 
swirling. The eNat tubes were then placed directly onto the 4,$V\PSKRQ\LQVWUXPHQW156 
DQGWKHDVVD\SHUIRUPHGDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV5HVLGXDOVDPSOH157 
YROXPHVZLWKLQWKHH1DWWXEHVIROORZLQJDQDO\VHVZHUHSURFHVVHGXVLQJWKHXpert 158 
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SA/Nasal Complete assay (Cepheid, Sunnyvale, CA, USA) on the GeneXpert 159 
automated platform according WRPDQXIDFWXUHU¶VLQVWUXFWLRQV. 160 
 161 
RESULTS 162 
 163 
Qiagen artus C. difficile assay 164 
The sensitivity, specificity, PPVs and NPVs of the artus C. difficile assay were all 100% 165 
(CI 95-100%) when the original results of the diagnostic laboratory algorithm 166 
(*'+&77 were adopted as the gold standard. Of the 100 GDH/CTT-positive samples 167 
re-tested against this algorithm, 96% remained both GDH and CTT positive. A 168 
breakdown of the discrepant results is displayed in Table I.  169 
 170 
4LDJHQDUWXV9DQ546-5*4DVVD\ 171 
The sensitivity, specificity, PPVs and NPVs of the artus VanR QS-RGQ assay were 172 
95% (19/20, 95% CI 73-100%), 68% (50/74, 95% CI 56-78%), 44% (19/43, 95% CI 29-173 
60) and 98% (50/51, 95% CI 88-100%) respectively where direct culture followed by 174 
MALDI-TOF analysis was adopted as the gold standard. The assay detected the vanA 175 
and/or vanB gene in 32% of culture negative VRE screens. In 71% of these cases 176 
(n=17), only vanB was detected; in 25% of cases (n=6), both vanA and vanB were 177 
detected with vanA alone being detected in the remaining 4% (n=1). 178 
 179 
Qiagen artus MRSA 46-5*4DVVD\ 180 
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Of the 200 nasal swabs previously analysed for presence of MRSA by culture, eight 181 
MRSA-positive and 32 MRSA-negative swabs gave either an invalid result (n = 19) or 182 
an error message (n = 21) with the Xpert SA Nasal Complete assay. The majority of the 183 
errors (95%) were due to probe check failures. This was most likely due to the off-label 184 
nature of the methodology, specifically the charcoal content of the swab transport 185 
medium. These samples were eliminated from the study and results from the remaining 186 
160 nasal swabs analysed. Adopting the original culture results as the gold standard, 187 
the sensitivity, specificity, PPV and NPV values for the artus assay were 64% (58/91, 188 
95% CI 53-73%), 94% (64/68, 95% CI 85-98%), 94% (58/62, 95% CI 84-98) and 66% 189 
(64/97, 95% CI 56-75) respectively, and for the Xpert assay, 74% (67/91, 95% CI 63-190 
82), 97% (66/68, 95% CI 89-99, 97% (67/69, 95% CI 89-99) and 73% (66/90, 95% CI 191 
72-90). The distribution of results obtained from both PCR assays is displayed in Table 192 
II. A total of 31 (19.4%) samples gave discordant results. The majority of discrepancies 193 
were results which were interpreted by the artus assay as S. aureus, but designated 194 
µQRWGHWHFWHG¶E\WKH;SHUWDVVD\39%), followed by results interpreted as MRSA by the 195 
Xpert assay, but designated S. aureus by the artus assay (32%). The majority of the 196 
results from this latter group (9/10) were found to be MRSA positive by culture.  197 
 198 
Of the 92 MRSA-positive swabs, only 71% were positive upon re-culture. There was 199 
good correlation between samples which were MRSA-positive upon re-culture, and 200 
those samples which were MRSA positive with one or both PCR assays. A second set 201 
of statistics was therefore calculated following elimination of results from all swabs that 202 
were MRSA-negative upon re-culturing; the sensitivity, specificity, PPV and NPV values 203 
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for the artus assay were then 80% (52/65, 95% CI 68-89), 94% (64/68, 95% CI 85-98), 204 
93% (52/56, 95% CI 82-98) and 83% (64/77, 95% CI 72-90), and for the Xpert assay, 205 
88% (57/65, 95% CI 77-94%), 97% (66/68, 95% CI 89-99), 97% (57/59, 95% CI 87-99) 206 
and 89% (66/74, 95% CI 79-95), respectively.  207 
DISCUSSION 208 
 209 
There is still conflicting opinion on optimal diagnosis of CDI worldwide [20-23]. 210 
Inaccurate laboratory results may lead to unnecessary treatment and isolation, and the 211 
true cause of the patients¶ diarrhoea not being further investigated (in the case of false 212 
positives), or cross-infection may occur with other patients and overtreatment with 213 
empirical antibiotics (in false-negative cases). A GDH test or NAAT are recommended 214 
for initial screening of samples because of their very high sensitivities, reported to be 215 
79.5-100% [8, 23, 24], followed by a sensitive toxin detection assay.  216 
 217 
In this study the performance of the artus C. difficile QS-RGQ assay was equivalent to 218 
that of a recommended two-step algorithm when testing samples retrospectively. A 219 
limitation of the study was that GDH-positive/CTT-negative samples were not included 220 
within the evaluation. However, although the sample selection is not necessarily 221 
representative of that seen in a routine hospital setting due to the proportion of positive 222 
samples being preselected, this is a useful evaluation of assay performance for the 223 
detection of true CDI positives and true CDI negatives. It is possible that excluding 224 
GDH-positive/CTT-negative samples may have slightly improved the performance of the 225 
artus C. difficile assay, however, this comparison most likely gives a more meaningful 226 
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result in the context of CDI diagnosis as such results do not represent CDI, but possible 227 
colonisation.  228 
 229 
It was noted that in previously CTT-positive samples that were toxin-negative upon re-230 
testing, it had either taken 48 hrs for a cytotoxic effect to occur in the initial test, or this 231 
effect had only been observed with an undiluted sample. This suggests that there were 232 
low levels of toxin in these samples. It is possible that toxin degradation during storage 233 
may have lowered the concentration further to an undetectable level. As PCR assays 234 
detect the presence of the toxin genes as opposed to the presence of free toxin, the 235 
artus assay has potential to identify faecal samples as toxin gene positive when they 236 
contain low toxin levels that are undetectable by CTT. Studies by Jazmati et al (2015) 237 
and Moon (2016) found the performance of the artus C. difficile to be comparable to that 238 
of the Xpert C. difficile PCR assay. [25, 26] It must be considered that a proportion of 239 
hospitalised patients may have toxigenic C. difficile with asymptomatic carriage and 240 
diarrhoea due to another cause. However, although a number of publications 241 
recommend that NAATs should not be used alone to diagnose CDI, [8, 24, 27, 28] some 242 
studies have found good correlation between toxin gene detection and clinical status of 243 
the patient. [29, 30]  244 
 245 
As the artus C. difficile assay (as with the further two artus assays evaluated) has a 246 
short turnaround time (3h 40 min for 24 samples which includes approximately 30-40 247 
mins hands on time), is user friendly, includes simple interpretation of results, has a 248 
high throughput (up to 72 per run) and offers flexibility of the associated platform for 249 
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detection of other organisms, this assay is a useful addition to the detection of CDI. As 250 
there is still no internationally accepted single method for CDI diagnosis, individual 251 
laboratories must decide which test will integrate best into their existing workflow. Two- 252 
or three-step approaches to the diagnosis of CDI could increase laboratory costs, but 253 
these might be offset by reduced total health care costs.  254 
 255 
Vancomycin-resistant enterococci 256 
As with CDIs, rapid and accurate detection of VRE is essential for adequate patient 257 
management including infection prevention measures. Traditional culture-based 258 
methods to detect these organisms are often time-consuming, taking up to several days 259 
to complete. A number of NAAT assays are now available that can detect either the 260 
vanA gene, or both vanA and vanB genes. Assays detecting both of these genes are 261 
desirable as a number of European countries have reported increasing numbers of 262 
colonisations and infections with vanB-type VRE. [12, 31]  263 
 264 
The sensitivity of the artus vanR assay in our study (95%) compares favourably with 265 
NAATs in previous studies [32]. Although the assay specificity was low (44%), it is 266 
possible that the false-positives recorded actually represented genuine VRE positive 267 
samples, where bacterial growth was not supported by the culture medium. High rates 268 
of vanB carriage have previously been reported in the absence of cultivable VRE in 269 
fecal/rectal samples and have mostly been attributed to one of two explanations. The 270 
first is that vanB-type resistance is sometimes difficult to detect since the vancomycin 271 
MIC of these strains FDQEHEHORZWKHDQWLPLFURELDOVXVFHSWLELOLW\EUHDNSRLQWRI272 
13 
 
mg/liter defined by the European Committee on Antimicrobial Susceptibility Testing. 273 
(EUCAST) [31, 33, 34] Secondly, non-enterococcal vanB genes could results in positive 274 
PCR results. These can be found in the gut, especially in anaerobic bacteria like 275 
Clostridium species. [32, 35-37] In our study the vanB gene alone was detected in 71% 276 
of these false-positive samples; our culture medium contained 6 mg/l vancomycin, and 277 
so either of these explanations is feasible. The artus VanR QS-RGQ assay may indeed 278 
be more sensitive for the detection of VRE isolates than culture due to the amplification 279 
of both vanA and vanB genes. However, further investigations on vanB positive (but 280 
vanA negative) isolates are needed to further knowledge here. If a patient population 281 
has high rates of faecal carriage of non-enterococcal species that contain vanB, an 282 
over-estimation of the rate of faecal VRE colonisation could result and potentially lead to 283 
unnecessary utilization of hospital resources and infection control prevention measures.  284 
 285 
MRSA 286 
Rapid and accurate detection of MRSA is required to minimize the spread of this 287 
organism in healthcare settings. Active screening currently forms an integral part of 288 
many MRSA infection control and prevention strategies, with several NAAT assays 289 
available for this purpose.  290 
 291 
Although the sensitivity values and NPVs of the artus and Xpert assays were low when 292 
calculated using the whole sample set, these values were much improved when the 293 
33% of swabs originally MRSA culture-positive, but negative upon re-culture, were 294 
eliminated from the calculations. It is likely that bacterial degradation occurred during 295 
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storage, and so these improved figures are more likely representative of assay 296 
performance during prospective testing. Our study was performed using an off-label 297 
method that incorporated charcoal-containing transport swabs. The invalid samples and 298 
the error messages from the Xpert assay were presumed to be due to interfering or 299 
inhibiting factors within the charcoal. The sensitivity of the Xpert assay (88%) is 300 
comparable to those of other MRSA PCR assays (82-93%), although the sensitivity of 301 
the artus assay was slightly lower at 80%.  302 
 303 
Specificities of both assays were relatively high (94% and 97% for the artus and Xpert 304 
assay, respectively) and compare well with other studies (78-99%). [38-42] In most 305 
cases (80.5%-90.5%), the two assays were in agreement as to whether MRSA, MSSA 306 
or no targets were present. The most common discordant combination was MSSA 307 
detected by the artus assay but no targets detected by the Xpert assay (12/160). 308 
However, in an MRSA screening programme, this would not affect patient management.  309 
The second most common discordant category was where the artus assay detected 310 
MSSA but the Xpert assay detected MRSA (10/160). Such results would affect patient 311 
management and are therefore of more concern. Almost all (9/10) of these samples 312 
were MRSA positive by culture, which suggests that the artus assay misidentified these 313 
samples. The Xpert assay, unlike the artus assay, does not detect mecC variants; 314 
however, only 2.6% of samples were designated MRSA by the artus assay only, and 315 
3/4 of these were culture-negative. This study therefore does not highlight lack of 316 
detection of mecC variants as a significant issue. Although the Xpert assay is rapid and 317 
15 
 
simple to use when processing smaller sample volumes, the artus assay is more 318 
efficient when processing larger volumes and is less costly per test.  319 
 320 
As with the artus C. difficile and VanR assays, the optimal choice of assay for MRSA 321 
screening should be determined according to user needs; for example, the artus MRSA 322 
assay would be more suited to a laboratory handling high volumes of screening swabs. 323 
The three artus assays all have high NPVs and are therefore especially suited to 324 
screening programmes. The assays can facilitate elimination of negative samples, 325 
meaning that confirmatory tests are only needed on a small proportion of these. This 326 
could reduce the hands on time required overall and lead to negative results being 327 
released more quickly. Additional laboratory-specific factors, including financial 328 
considerations and technical expertise, will also be important in deciding between 329 
screening methods. 330 
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 545 
Table II: Distribution of results obtained from the artus MRSA and GeneXpert 546 
SA/Nasal assays  547 
artus MRSA result Xpert SA/Nasal result No. of samples (%)  
 
No. of samples 
culture positive 
(%a) 
MRSA  MRSA 58 (36.3)  57 (98) 
MRSA MSSA 3 (2.0)  0 (0) 
MRSA No targets detected 1 (0.6)  1 (100) 
MSSA MRSA 10 (6.3)  9 (90) 
MSSA MSSA 18 (11.3) 3 (16.7) 
MSSA No targets detected 12 (7.5) 5 (41.7) 
No targets detected MRSA 1 (0.6)  1 (100) 
No targets detected MSSA 4 (2.5) 1 (25) 
No targets detected No targets detected 53 (33.0) 15 (28) 
a
 denominator being the number of samples within each individual category 548 
